Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

NCT03916419 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03916419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03916419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2019
Completion date
September 28, 2025
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iib non-small cell lung cancer, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iiic non-small cell lung cancer